

## Public Health Evidence Report Following Engagement Activity

This form is to be completed by the Policy Working Groups Public Health Lead if stakeholders identify potential new evidence during policy development engagement activities. The Public Health Lead will assess the evidence raised to against the Population, Intervention, Comparator and Outcome (PICO) criteria and will record the studies in the appropriate boxes in the '*Outcome for studies suggested during engagement activities*' section of this form. In cases where newly identified evidence has a material impact please return the completed form to the Clinical Effectiveness Team (CET).

<b>URN</b>	2110
<b>Policy title:</b>	Dabrafenib and trametinib for anaplastic thyroid cancer with BRAF mutation
<b>CRG:</b>	Chemotherapy
<b>NPOC:</b>	Cancer
<b>Engagement activity</b>	Stakeholder engagement
<b>Date</b>	

<b>Description of comments during engagement (If studies have been suggested please provide a list of references)</b>	<p>Stakeholders asked for the findings and relevance of the following study to be considered in the development of the policy:</p> <ul style="list-style-type: none"> <li><i>Subbiah, V et al, 2022, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study, Annals of Oncology, Vol 33:pages 406-415</i></li> </ul>
<b>Action taken by Public Health lead</b>	The paper was reviewed against the original PICO criteria for the evidence review that informed the policy proposition.
<b>Outcome for studies suggested during engagement activities</b>	

<b>1. Evidence already identified during the evidence review</b>	None.
<b>2. New evidence identified by stakeholders that does not fall within PICO and search methodology</b>	<ul style="list-style-type: none"> <li>• <i>Subbiah, V et al, 2022, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study, Annals of Oncology, Vol 33:pages 406-415</i></li> </ul> <p>This study was published after the search strategy was run (27th July 2021). However, it did meet the other PICO criteria and it was therefore assessed.</p> <p>This study was an updated analysis (containing the full enrolment of 36 patients with approximately 4 years of safety follow up) of a Phase II study (Subbiah et al 2018) already included in the existing evidence review. The results of this updated analysis are consistent with the findings in Subbiah et al 2018 and do not materially affect the conclusions of the existing evidence review.</p>
<b>3. New evidence identified by stakeholders that falls within PICO and search methodology but does not materially affect the conclusions of the existing evidence review</b>	None.
<b>4. New evidence identified by stakeholders that falls within PICO and search methodology, that does materially affect the conclusions of the existing evidence review. Updated evidence review to be undertaken (to be agreed with CET)</b>	None.

Completed by:	PWG Public Health Lead
Date:	9.6.22